



City of Cambridge

38.

IN CITY COUNCIL

January 27, 1997

COUNCILLOR SULLIVAN
VICE MAYOR BORN
COUNCILLOR DAVIS
COUNCILLOR DUEHAY
COUNCILLOR GALLUCCIO
COUNCILLOR REEVES
MAYOR RUSSELL
COUNCILLOR TOOMEY
COUNCILLOR TRIANTAFILLOU

WHEREAS: It has come to the attention of this City Council that **Hybridon, Inc.**, a growing bio-medical company with new offices in Cambridge, has received a United States patent for its method of orally administering a class of specialized agents for attacking human colon cancer cells; now therefore be it

RESOLVED: That the City Council go on record congratulating Hybridon, Inc., for its exciting new achievement; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to **Hybridon, Inc.** on behalf of the entire City Council.

In City Council January 27, 1997
Adopted by the affirmative vote of nine members.
Attest:- D. Margaret Drury, City Clerk.

A true copy;

A handwritten signature in cursive script, reading "D. Margaret Drury".

ATTEST:-

D. Margaret Drury
City Clerk

Mass

Replaces # 38

Whereas It has come to the attention of this City Council that Hybridon, Inc, a growing Worcester-based business with new offices in Cambridge, has received a United States patent for its method of orally administering a class of specialized agents for attacking human colon cancer cells; and now therefore be it

~~Whereas~~

Resolved: That the C-C go on record congratulating Hybridon, Inc, for its exciting new achievement; and be it further

Resolved: SEC to Hybridon, Inc, on behalf of the entire C-C

Hybridon gets patent for oral delivery of drug

Worcester-based Hybridon Inc. said it received a US patent for its method of orally administering a class of specialized agents for attacking human colon cancer cells. In a press release, the company said scientific testing on rats indicated the antisense agents, when administered orally, can inhibit tumor growth to the same extent and with the same dosage as those given intravenously. A Hybridon spokesman said many scientists thought the agent molecules were too large to be given orally, but the company developed a liquified version of the drug. Hybridon discovers and develops genetic medicines based on antisense technology, which involves the use of synthetic segments of DNA to create compounds that block the sending of improper genetic information within cells. Hybridon shares fell $\frac{1}{4}$ to $\frac{5}{8}$. (Dow Jones)

Sullivan

RECEIVED BY
OFFICE OF CITY CLERK
97 JAN 21 AM 9:22
CAMBRIDGE MA.

38.

Congratulations to Hiberdon
(in Business Section - Globe)

39.

Best wishes for speedy recovery
to Joan Lorenty.



City of Cambridge

38.

IN CITY COUNCIL

January 27, 1997

COUNCILLOR SULLIVAN

WHEREAS: It has come to the attention of this City Council that **Hybridon, Inc.**, a growing Worcester-based with new offices in Cambridge, has received a United States patent for its method of orally administering a class of specialized agents for attacking human colon cancer cells; now therefore be it

RESOLVED: That the City Council go on record congratulating Hybridon, Inc., for its exciting new achievement; and be it further

RESOLVED: That the City Clerk be and hereby is requested to forward a suitably engrossed copy of this resolution to **Hybridon, Inc.** on behalf of the entire City Council.

Consent Order #38

Entre
Membership

Councillor Sullivan re: Congratulations
to Hybridon, Inc., on receiving a
United States patent for its method of
orally administering a class of specialized
agents for attacking human colon cancer
cells.

R-141

In City Council January 27, 1997

ORDER ADOPTED